Thermo Fisher Scientific has announced that it will be investing up to $40M to upgrade its single-use technology manufacturing facility in Millersburg, Pennsylvania.
The expansion will "help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19," according to the company.
The announcement is part of a $650 million bioprocessing investment unveiled last year, which includes the expansion of the soon-to-be 47,000 square foot warehouse that should be fully renovated by mid-2023 and will create close to 100 new jobs.
Since the start of the pandemic, the Millersburg site has supported more than 20 pharmaceutical partners developing lifesaving therapies and vaccines, says Thermo Fisher. “During the pandemic, our colleagues in Millersburg and around the world answered the call for increased production,” Mitch Kennedy, president of single-use technologies at Thermo Fisher Scientific, said in a statement. “Our expanded bioprocessing capabilities will ensure that we can continue to deliver essential supplies to our customers as demand surges.”
Last September Thermo Fisher unveiled plans to build a dedicated single-use technology plant in Nashville. The facility could more than double the company’s single-use capacity and become one of the largest single-use manufacturing sites in the world, they announced.
Beyond Nashville, the company has been looking to ramp up its single-use production capacity at sites in Utah, the UK, Singapore and China. The company’s single-use technologies facility in Singapore has already opened for business, they announced.
“We are tremendously grateful for the vision, investment and job creation Thermo Fisher Scientific is bringing to Millersburg and our hardworking local families,” said U.S. Representative Scott Perry (PA-10). “We know our folks will continue to make this world-class company and our community proud.”
